Highlighting the Latest Advancements in Bladder Cancer
Thomas W. Flaig, MD, discusses the most dramatic change in the treatment landscape for patients with advanced bladder cancer. Over the last several years, 5 checkpoint inhibitors have been approved in this space.
Thomas W. Flaig, MD, professor and associate dean for clinical research, Genitourinary Cancer Program, Division of Medical Oncology, University of Colorado, discusses the most dramatic change in the treatment landscape for patients with advanced bladder cancer. Over the last several years, 5 checkpoint inhibitors have been approved in this space.
Checkpoint inhibitors are leading to response rates in the 20% to 25% range as monotherapy. Flaig says he would like to see higher response rates. Both patients and providers want durable responses that are well tolerated, and checkpoint inhibitors appear promising in that respect.
